Uncategorized

Santersus AG today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its NucleoCapture™ blood purification technology for the treatment of severe, treatment-refractory systemic lupus erythematosus (SLE). This marks the second Breakthrough Device Designation awarded to NucleoCapture™, following earlier recognition for the treatment of sepsis. NucleoCapture™ is an extracorporeal …

Santersus AG Receives Second U.S. FDA Breakthrough Device Designation for NucleoCapture™ in Systemic Lupus Erythematosus Read More »

December 3, 2024 – Santersus AG presented its groundbreaking NucleoCapture technology at the prestigious BRAIN Conference 2024 in London. The event brought together global experts to advance neurovascular research and discuss cutting-edge developments in brain health. Elevated cfDNA levels are associated with brain injuries and disorders, making it a potential biomarker for diagnosing and monitoring …

Santersus AG Showcases Innovation in Brain Health at BRAIN Conference 2024 Read More »

Santersus AG is proud to announce the successful publication of its latest research, “Restoring discarded porcine lungs by ex vivo removal of neutrophil extracellular traps”, in the prestigious Journal of Heart and Lung Transplantation. This innovative work offers a transformative solution to address the global shortage of viable lungs for transplantation, utilizing advanced ex vivo …

Santersus AG Achieves Breakthrough in Lung Transplantation Research Read More »

Santersus AG has been recognized as a National Abstract Winner at the prestigious UK ECPR Summit, held at the Royal Society of Medicine on Monday, September 23rd 2024. The award highlights the company’s pioneering research on selective cell-free DNA/NETs apheresis with NucleoCapture, presented in a highly acclaimed poster at the critical care section of the event. This innovative …

Santersus AG Wins National Abstract Award at UK ECPR Summit for Groundbreaking Research in Critical Care Read More »

In May, Dr Fungai Dengu (DPhil, PhD Candidate, Transplant Surgery, University of Oxford) and Dr. Hussain Abbas (DPhil, Transplant Surgery, University of Oxford) represented Santersus AG in the 2024 International Congress of ILTS, held in Houston (Texas, USA). The main presentation, which got featured in the best of basic science session, investigated the ability of …

Santersus AG Presented at the 2024 International Congress of ILTS in Houston, Texas Read More »

In May, Dr Fungai Dengu (DPhil, PhD Candidate, Transplant Surgery, University of Oxford) represented Santersus AG in ILTS 2023 Congress on Liver Transplantation, held in Rotterdam where he presented a Santersus study, aimed to investigate the effect of removal of NETs on reduction of ex-situ reperfusion injury in porcine DCD livers preserved with normothermic machine …

Santersus AG continues to present the latest work across the globe, presenting at conferences in Berlin, Rotterdam, Athens, and Milan Read More »

In the beginning of March, Dr Fungai Dengu (DPhil, PhD Candidate, Transplant Surgery, University of Oxford) represented Santersus AG at BTS conference, held in Edinburgh where he presented a recent Santersus study, aimed to investigate the effect of removal of NETs on reduction of ex-situ reperfusion injury in porcine DCD livers preserved with normothermic machine …

Santersus AG presented at NHSBT Joint Congress, held by British Transplantation Society Read More »

At the end of February, Andrew Aswani, MD, PhD (Santersus AG Chief Medical Officer) participated in the 10th Annual UC San Diego Essentials & Advances in Apheresis Therapies. Dr. Aswani had the opportunity to share current success regarding Santersus and our development of the selective therapeutic cell-free DNA/NET apheresis device to a large audience of …

Santersus AG presented at Apheresis Conference at the University of California San Diego Read More »

A study, published on Jan. 20 in PNAS, identifies cell-free DNA as a highly versatile analyte for monitoring of the most important complications of hematopoietic cell transplantation: Graft-Versus-Host Disease, infection, graft failure and disease relapse. Hematopoietic cell transplantation is the gold standard treatment for many blood disorders, including blood cancers. Nonetheless, frequent post-transplant complications limit …

Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation Read More »

Santersus AG is proud to be recognized as a top innovator and to be granted a presentation slot at the transCampus Partnership 10 year Anniversary Event in London on February 13, 2023. The transCampus partnership, which is overseen by joint Dean, Professor Stefan Bornstein includes joint professorships, administrative structures and training programmes for students from the …

Santersus AG Presented at transCampus Partnership Event in London Read More »